Livemint EN

Stock to buy: Avendus initiates coverage on Dr Agarwal’s Health Care with 'buy' rating; sees 18.3% upside

Avendus Spark Institutional Equities has initiated coverage on Dr. Agarwal’s Health Care, giving it a 'buy' rating and a target price of ₹495. The company is well-positioned in the eye care market, anticipating strong growth driven by acquisitions and surgical revenues.

Mar 24, 2026 &03292424202631; 13:29 UTC www.livemint.com Trending 4/5

Read original on www.livemint.com ↗

↗

Positive for markets

Sentiment score: +62/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Avendus initiates 'buy' coverage on Dr Agarwal's Health Care with ₹495 target (18.3% upside), citing strong eye care market positioning and acquisition-driven growth. Fresh analyst initiation is a positive catalyst, but market context shows broad US equity weakness (-0.69% S&P 500, VIX +4.7%) which may limit immediate upside.

AI CONFIDENCE

58% Moderate

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

DRAGARWAL.NS

DRAGARWAL.NSStock

Expected to rise

Fresh analyst initiation with 'buy' rating and 18.3% upside target provides positive catalyst; eye care sector tailwinds and M&A growth story support thesis

↓

S&P 500

^GSPCIndex

Expected to decline

Broad market weakness (-0.69%) and elevated VIX (27.38, +4.7%) suggest risk-off sentiment may cap individual stock gains despite positive news

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Buy signal is valid but confidence is moderate due to macro headwinds (S&P weakness, high VIX). Wait for market stabilization or enter on dips if conviction is high; avoid chasing into broad selloff. Monitor if Dr Agarwal's decouples from index weakness. [MOVE:1.2%]

KEY SIGNALS

Fresh analyst initiation (Avendus) — not yet fully absorbed by market18.3% upside target provides clear price objectiveAcquisition-driven growth narrative + surgical revenue expansionHeadwind: Broad market weakness and elevated fear (VIX +4.7%)

SECTORS INVOLVED

HealthcareEye Care / Ophthalmology

Analysis generated on Mar 24, 2026 at 13:46 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Livemint. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Stock to buy: Avendus initiates coverage on Dr Agarwal’s Health Care with 'buy' rating; sees 18.3% upside

RELATED INTELLIGENCE